Catherine A Blish

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. ncbi Transmission of HIV-1 in the face of neutralizing antibodies
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Curr HIV Res 5:578-87. 2007
  2. pmc Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Virol 84:2573-84. 2010
  3. pmc Hormonal contraception and HIV-1 transmission
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Am J Reprod Immunol 65:302-7. 2011
  4. pmc Genital Inflammation Predicts HIV-1 Shedding Independent of Plasma Viral Load and Systemic Inflammation
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 61:436-40. 2012
  5. pmc Systemic cytokine levels show limited correlation with risk of HIV-1 acquisition
    Dara A Lehman
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Global Health, University of Washington, Seattle, WA Department of Medicine, Stanford Immunology, Stanford University School of Medicine, Stanford, CA Departments of Medicine Epidemiology, University of Washington, Seattle, WA Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya Coast Provincial General Hospital, Women s Health Project, Mombasa, Kenya Department of Biostatistics, University of Washington, Seattle, WA Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
    J Acquir Immune Defic Syndr 66:135-9. 2014
  6. pmc Association between cellular immune activation, target cell frequency, and risk of human immunodeficiency virus type 1 superinfection
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Virol 88:5894-9. 2014
  7. pmc Cellular immune responses and susceptibility to HIV-1 superinfection: a case-control study
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA
    AIDS 26:643-6. 2012
  8. pmc Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Seattle, WA 98109 1024, USA
    J Virol 83:7783-8. 2009
  9. pmc Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression
    Anne Piantadosi
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Virol 83:10269-74. 2009
  10. pmc Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Virol 82:12094-103. 2008

Detail Information

Publications15

  1. ncbi Transmission of HIV-1 in the face of neutralizing antibodies
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Curr HIV Res 5:578-87. 2007
    ....
  2. pmc Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Virol 84:2573-84. 2010
    ....
  3. pmc Hormonal contraception and HIV-1 transmission
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Am J Reprod Immunol 65:302-7. 2011
    ..It is clear that hormonal contraceptives are not protective against HIV-1 infection and that dual protection with condoms should be the goal for women using hormonal contraception...
  4. pmc Genital Inflammation Predicts HIV-1 Shedding Independent of Plasma Viral Load and Systemic Inflammation
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 61:436-40. 2012
    ..Thus, efforts to decrease HIV-1 transmission must take into account the role of local inflammation, which is not necessarily reflected in plasma measurements...
  5. pmc Systemic cytokine levels show limited correlation with risk of HIV-1 acquisition
    Dara A Lehman
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA Department of Global Health, University of Washington, Seattle, WA Department of Medicine, Stanford Immunology, Stanford University School of Medicine, Stanford, CA Departments of Medicine Epidemiology, University of Washington, Seattle, WA Department of Medical Microbiology, University of Nairobi, Nairobi, Kenya Coast Provincial General Hospital, Women s Health Project, Mombasa, Kenya Department of Biostatistics, University of Washington, Seattle, WA Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
    J Acquir Immune Defic Syndr 66:135-9. 2014
    ..Inconsistent results within our study and among previous studies suggest that reproducible findings are needed before cytokines are useful biomarkers for HIV-1 susceptibility...
  6. pmc Association between cellular immune activation, target cell frequency, and risk of human immunodeficiency virus type 1 superinfection
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Virol 88:5894-9. 2014
    ..7-fold increase in the odds of superinfection. This suggests that HIV-1 acquisition risk is influenced more by the frequency of target cells than by the generalized level of immune activation. ..
  7. pmc Cellular immune responses and susceptibility to HIV-1 superinfection: a case-control study
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA
    AIDS 26:643-6. 2012
    ....
  8. pmc Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave North, Seattle, WA 98109 1024, USA
    J Virol 83:7783-8. 2009
    ..However, significant cross-subtype neutralization by plasma was observed, indicating that there may be other epitopes, not yet defined by the limited available MAbs, which could be recognized more broadly...
  9. pmc Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression
    Anne Piantadosi
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Virol 83:10269-74. 2009
    ..Thus, a broad NAb response results from a high level of antigenic stimulation early in infection, which likely accounts for prior observations that greater NAb response breadth is associated with a higher viral load later in infection...
  10. pmc Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Virol 82:12094-103. 2008
    ..These data indicate that preventing infection by vaccination will likely require broader and more potent NAb responses than those found in HIV-1-infected individuals...
  11. pmc Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS Med 5:e9. 2008
    ..Using a naturally occurring HIV-1 Envelope (Env) variant as a template, we sought to identify features of Env that would enhance exposure of conserved HIV-1 epitopes...
  12. pmc The breadth and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies do not correlate with the risk of infant infection
    John B Lynch
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Virol 85:5252-61. 2011
    ....
  13. pmc The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization
    Erica Lovelace
    Divisions of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Virology 421:235-44. 2011
    ..This finding suggests that antibody neutralization may occur through a multi-step pathway that includes distinct changes in envelope conformation that may affect binding but not neutralization susceptibility...
  14. ncbi HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    AIDS 21:693-702. 2007
    ..An effective HIV-1 vaccine or microbicide must block the transmitted virus variants that initially establish a new infection; consequently, it is critical that such viruses be isolated and characterized...
  15. pmc Changes in plasma cytokines after treatment of ascaris lumbricoides infection in individuals with HIV-1 infection
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98104, USA
    J Infect Dis 201:1816-21. 2010
    ..Treatment of A. lumbricoides co-infection may delay HIV-1 disease progression by reducing helminth-induced, IL-10-mediated immunosuppression...